Ads
related to: taxotere prostate cancer survival rates by age 40cancer.osu.edu has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Docetaxel (DTX or DXL), sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer. [6] This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. [7] It may be used by itself or along with other chemotherapy medication. [6]
James, Sydes & Clarke 2016 reported that "the addition of docetaxel to standard of care was associated with improved survival, with an HR of 0·78 and a difference in median survival of 10 months, as well as improvements in prostate-cancer-specific survival, failure-free survival, and skeletal-related events".
For men over 64 with prostate cancer limited to the pelvis, using fewer, larger doses of radiation (hypofractionation) results in similar overall survival rates. [28] The risk of dying from prostate cancer or having acute bladder side effects may be similar to that of longer radiation treatment. [28]
In fact, the five-year survival rate for prostate cancer detected early is virtually 100%, Siddiqui says. The outlook for late-diagnosed patients, however, is not nearly as rosy.
Most men diagnosed have tumors confined to the prostate; 99% of them survive more than 10 years from their diagnoses. Tumors that have metastasized to distant body sites are most dangerous, with five-year survival rates of 30–40%. The risk of developing prostate cancer increases with age; the average age of diagnosis is 67.
In males, researchers suggest that the overall reduction in cancer death rates is due in large part to a reduction in tobacco use over the last half century, estimating that the reduction in lung cancer caused by tobacco smoking accounts for about 40% of the overall reduction in cancer death rates in men and is responsible for preventing at least 146,000 lung cancer deaths in men during the ...
Ads
related to: taxotere prostate cancer survival rates by age 40